Literature DB >> 25401716

Relapse prevention after index electroconvulsive therapy in treatment-resistant depression.

Nagy A Youssef1, W Vaughn McCall.   

Abstract

BACKGROUND: One-third of patients who suffer from depression are resistant to conventional treatments. An acute course of electroconvulsive therapy (ECT) can lead to remission of depressive symptoms in a substantial portion of the treatment-resistant patients. However, prevention of relapse with depressive symptoms after the index course of ECT can be challenging. We review pertinent studies on the topic and analyze the best strategies to avoid relapse and recurrence of depressive symptoms.
METHODS: We performed a systematic literature review of PubMed through April 2014 for clinical trials published in English to determine if continuation ECT (C-ECT), continuation medication, continuation psychotherapy, or combinations of these are the best strategy to avoid relapse and recurrence of depressive symptoms after an acute course of ECT. Clinical trials comparing ≥2 of the above strategies were included in the review.
RESULTS: Although there are few rigorous randomized clinical trials in this area, most studies suggest that combined C-ECT and continuation pharmacotherapy are the most effective strategy in relapse prevention.
CONCLUSIONS: C-ECT and continuation pharmacotherapy may be more effective than either alone for preventing relapse. However, more definitive randomized clinical trials are needed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25401716      PMCID: PMC4420179     

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  50 in total

1.  Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Wai Tat Chiu; Olga Demler; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

2.  Maintenance electroconvulsive therapy in affective and schizoaffective disorder.

Authors:  E Swoboda; A Conca; P König; R Waanders; M Hansen
Journal:  Neuropsychobiology       Date:  2001-01       Impact factor: 2.328

3.  A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities.

Authors:  H A Sackeim; J Prudic; D P Devanand; M S Nobler; S H Lisanby; S Peyser; L Fitzsimons; B J Moody; J Clark
Journal:  Arch Gen Psychiatry       Date:  2000-05

4.  Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).

Authors:  Charles H Kellner; Rebecca G Knapp; Georgios Petrides; Teresa A Rummans; Mustafa M Husain; Keith Rasmussen; Martina Mueller; Hilary J Bernstein; Kevin O'Connor; Glenn Smith; Melanie Biggs; Samuel H Bailine; Chitra Malur; Eunsil Yim; Shawn McClintock; Shirlene Sampson; Max Fink
Journal:  Arch Gen Psychiatry       Date:  2006-12

5.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire.

Authors:  R L Spitzer; K Kroenke; J B Williams
Journal:  JAMA       Date:  1999-11-10       Impact factor: 56.272

6.  Efficiency of outpatient ECT.

Authors:  Rachel Dew; W Vaughn McCall
Journal:  J ECT       Date:  2004-03       Impact factor: 3.635

7.  The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression.

Authors:  H A Sackeim; J Prudic; D P Devanand; P Decina; B Kerr; S Malitz
Journal:  J Clin Psychopharmacol       Date:  1990-04       Impact factor: 3.153

Review 8.  The management of treatment-resistant depression in the medically ill.

Authors:  K Franco-Bronson
Journal:  Psychiatr Clin North Am       Date:  1996-06

9.  Data management and design issues in an unmasked randomized trial of electroconvulsive therapy for relapse prevention of severe depression: the consortium for research in electroconvulsive therapy trial.

Authors:  Keith G Rasmussen; Rebecca G Knapp; Melanie M Biggs; Glenn E Smith; Teresa A Rummans; Georgios Petrides; Mustafa M Husain; M Kevin O'Connor; Max Fink; Charles H Kellner
Journal:  J ECT       Date:  2007-12       Impact factor: 3.635

10.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

View more
  4 in total

1.  Is Conduct of Research in Electroconvulsive Therapy Ethical?

Authors:  N A Youssef; W V McCall
Journal:  J Psychol Neuropsychiatr Disord Brain Stimul       Date:  2016-05-13

2.  Perils of Pragmatic Psychiatry: How We Can Do Better.

Authors:  Maju Mathew Koola; Joseph Sebastian
Journal:  HSOA J Psychiatry Depress Anxiety       Date:  2016-02-23

3.  Double-Blinded Randomized Pilot Clinical Trial Comparing Cognitive Side Effects of Standard Ultra-Brief Right Unilateral ECT to 0.5 A Low Amplitude Seizure Therapy (LAP-ST).

Authors:  Nagy A Youssef; William V McCall; Dheeraj Ravilla; Laryssa McCloud; Peter B Rosenquist
Journal:  Brain Sci       Date:  2020-12-13

4.  The Immediate Early Gene Egr3 Is Required for Hippocampal Induction of Bdnf by Electroconvulsive Stimulation.

Authors:  Kimberly T Meyers; Ketan K Marballi; Samuel J Brunwasser; Briana Renda; Milad Charbel; Diano F Marrone; Amelia L Gallitano
Journal:  Front Behav Neurosci       Date:  2018-05-11       Impact factor: 3.558

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.